Wellington Management Holds 13.9% of Celldex Therapeutics Shares—Key SEC UpdateWellington Management Group now owns 13.9% of Celldex Therapeutics, a biotech innovator in autoimmune, cancer, and cardiovascular treatments.CELLDEX THERAPEUTICS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 18/11/2026, 18:07 One minute to read